journal
https://read.qxmd.com/read/38360055/pet-ct-based-radiogenomics-supports-keap1-nfe2l2-pathway-targeting-for-non-small-cell-lung-cancer-treated-with-curative-radiotherapy
#61
JOURNAL ARTICLE
Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, Ulrike Schick
In lung cancer patients, radiotherapy is associated with a increased risk of local relapse (LR) when compared with surgery but with a preferable toxicity profile. The KEAP1/NFE2L2 mutational status (MutKEAP1/NFE2L2 ) is significantly correlated with LR in patients treated with radiotherapy but is rarely available. Prediction of MutKEAP1/NFE2L2 with noninvasive modalities could help to further personalize each therapeutic strategy. Methods: Based on a public cohort of 770 patients, model RNA (M-RNA) was first developed using continuous gene expression levels to predict MutKEAP1/NFE2L2 , resulting in a binary output...
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360054/example-of-artificial-intelligence-based-decision-support-for-amino-acid-pet-early-prediction-of-suspected-brain-tumor-foci-for-patient-management
#62
JOURNAL ARTICLE
Philipp Lohmann, Robin Gutsche, Jan-Michael Werner, N Jon Shah, Karl-Josef Langen, Norbert Galldiks
No abstract text is available yet for this article.
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360053/the-detect-trial-are-we-on-the-verge-of-precision-surgery-in-primary-prostate-cancer
#63
JOURNAL ARTICLE
Tobias Maurer, Christian Thomas, Boris Hadaschik
No abstract text is available yet for this article.
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360052/first-in-human-study-of-18-f-synvest-2-an-sv2a-pet-imaging-probe-with-fast-brain-kinetics-and-high-specific-binding
#64
JOURNAL ARTICLE
Lindsey R Drake, Yanjun Wu, Mika Naganawa, Ruth Asch, Chao Zheng, Soheila Najafzadeh, Richard Pracitto, Marcel Lindemann, Songye Li, Jim Ropchan, David Labaree, Paul R Emery, Mark Dias, Shannan Henry, Nabeel Nabulsi, David Matuskey, Ansel T Hillmer, Jean-Dominique Gallezot, Richard E Carson, Zhengxin Cai, Yiyun Huang
PET imaging of synaptic vesicle glycoprotein 2A allows for noninvasive quantification of synapses. This first-in-human study aimed to evaluate the kinetics, test-retest reproducibility, and extent of specific binding of a recently developed synaptic vesicle glycoprotein 2A PET ligand, ( R )-4-(3-(18 F-fluoro)phenyl)-1-((3-methylpyridin-4-yl)methyl)pyrrolidine-2-one (18 F-SynVesT-2), with fast brain kinetics. Methods: Nine healthy volunteers participated in this study and were scanned on a High Resolution Research Tomograph scanner with 18 F-SynVesT-2...
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360051/effectiveness-of-225-ac-labeled-anti-egfr-radioimmunoconjugate-in-egfr-positive-kirsten-rat-sarcoma-viral-oncogene-and-braf-mutant-colorectal-cancer-models
#65
JOURNAL ARTICLE
Anjong Florence Tikum, Jessica P Ketchemen, Alireza Doroudi, Anand K Nambisan, Hanan Babeker, Fabrice Ngoh Njotu, Humphrey Fonge
Eighty percent of colorectal cancers (CRCs) overexpress epidermal growth factor receptor (EGFR). Kirsten rat sarcoma viral oncogene (KRAS) mutations are present in 40% of CRCs and drive de novo resistance to anti-EGFR drugs. BRAF oncogene is mutated in 7%-10% of CRCs, with even worse prognosis. We have evaluated the effectiveness of [225 Ac]Ac-macropa-nimotuzumab in KRAS mutant and in KRAS wild-type and BRAFV600E mutant EGFR-positive CRC cells in vitro and in vivo. Anti-CD20 [225 Ac]Ac-macropa-rituximab was developed and used as a nonspecific radioimmunoconjugate...
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360050/molecular-imaging-of-acute-graft-versus-host-disease
#66
JOURNAL ARTICLE
Chiara Bernardi, Valentina Garibotto, Behnaz Mobashwera, Robert S Negrin, Israt S Alam, Federico Simonetta
Noninvasive molecular imaging of acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation has great potential to detect GvHD at the early stages, aid in grading of the disease, monitor treatment response, and guide therapeutic decisions. Although the specificity of currently available tracers appears insufficient for clinical GvHD diagnosis, recently, several preclinical studies have identified promising new imaging agents targeting one or more biologic processes involved in GvHD pathogenesis, ranging from T-cell activation to tissue damage...
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360049/need-for-objective-task-based-evaluation-of-image-segmentation-algorithms-for-quantitative-pet-a-study-with-acrin-6668-rtog-0235-multicenter-clinical-trial-data
#67
JOURNAL ARTICLE
Ziping Liu, Joyce C Mhlanga, Huitian Xia, Barry A Siegel, Abhinav K Jha
Reliable performance of PET segmentation algorithms on clinically relevant tasks is required for their clinical translation. However, these algorithms are typically evaluated using figures of merit (FoMs) that are not explicitly designed to correlate with clinical task performance. Such FoMs include the Dice similarity coefficient (DSC), the Jaccard similarity coefficient (JSC), and the Hausdorff distance (HD). The objective of this study was to investigate whether evaluating PET segmentation algorithms using these task-agnostic FoMs yields interpretations consistent with evaluation on clinically relevant quantitative tasks...
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38360048/the-potential-contribution-of-radiopharmaceutical-therapies-in-managing-oligometastatic-disease
#68
JOURNAL ARTICLE
Amar U Kishan, Shankar Siva, Michael S Hofman, James Nagarajah, Ana P Kiess, Phuoc Tran, Jeremie Calais
There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease as an alternative to or as a means of delaying systemic therapy. Unfortunately, MDT often does not provide a durable cure, and progression-particularly progression in multiple new areas-remains a concern...
February 15, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38331457/somatostatin-receptor-imaging-with-18-f-fet-%C3%AE-ag-toca-pet-ct-and-68-ga-ga-dota-peptide-pet-ct-in-patients-with-neuroendocrine-tumors-a-prospective-phase-2-comparative-study
#69
JOURNAL ARTICLE
Suraiya Dubash, Tara D Barwick, Kasia Kozlowski, Andrea G Rockall, Sairah Khan, Sameer Khan, Siraj Yusuf, Angela Lamarca, Juan W Valle, Richard A Hubner, Mairéad G McNamara, Andrea Frilling, Tricia Tan, Florian Wernig, Jeannie Todd, Karim Meeran, Bhavesh Pratap, Saleem Azeem, Michael Huiban, Nicholas Keat, Jingky P Lozano-Kuehne, Eric O Aboagye, Rohini Sharma
There is a clinical need for 18 F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [68 Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [18 F]fluoroethyl-triazole-[Tyr3 ]-octreotate ([18 F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of [18 F]FET-βAG-TOCA PET/CT compared with [68 Ga]Ga-DOTA- peptide PET/CT in patients with NET...
February 8, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38331456/sstr-antagonists-as-theranostic-option-in-merkel-cell-carcinoma
#70
JOURNAL ARTICLE
Malte Kircher, Adriana Amerein, Mareike Augustin, Nic G Reitsam, Johanna S Enke, Marianne Patt, Georgine Wienand, Ralph A Bundschuh, Christian H Pfob, Constantin Lapa, Alexander Dierks
No abstract text is available yet for this article.
February 8, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38331455/molecular-imaging-in-breast-cancer-martine-piccart-and-g%C3%A3-raldine-gebhart-talk-with-david-mankoff-about-2-generations-of-research
#71
JOURNAL ARTICLE
Géraldine Gebhart, Martine Piccart, David Mankoff
No abstract text is available yet for this article.
February 8, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38331454/aruna-bodapati-gambhir-1962-2023
#72
JOURNAL ARTICLE
Christian Behrenbruch, Andrei Iagaru, Michelle L James
No abstract text is available yet for this article.
February 8, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38331453/diagnostic-accuracy-of-68-ga-fapi-versus-18-f-fdg-pet-in-patients-with-various-malignancies
#73
JOURNAL ARTICLE
Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Lukas Kessler, Kim M Pabst, Francesco Barbato, Helena Lanzafame, Stefan Kasper, Michael Nader, Claudia Kesch, Bastian von Tresckow, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Boris Hadaschik, Viktor Grünwald, Jens T Siveke, Ken Herrmann, Wolfgang P Fendler
To assess the diagnostic accuracy of 68 Ga-labeled fibroblast activation protein inhibitor (FAPI) and 18 F-labeled FDG PET for the detection of various tumors, we performed a head-to-head comparison of both imaging modalities across a range of tumor entities as part of our ongoing 68 Ga-FAPI PET observational trial. Methods: The study included 115 patients with 8 tumor entities who received imaging with 68 Ga-FAPI for tumor staging or restaging between October 2018 and March 2022. Of those, 103 patients received concomitant imaging with 68 Ga-FAPI and 18 F-FDG PET and had adequate lesion validation for accuracy analysis...
February 8, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38302152/one-year-longitudinal-changes-in-tau-accumulation-on-18-f-pi-2620-pet-in-the-alzheimer-spectrum
#74
JOURNAL ARTICLE
Minyoung Oh, Seung Jun Oh, Sang Ju Lee, Jungsu S Oh, Seung Yeon Seo, Soorack Ryu, Jee Hoon Roh, Jae-Hong Lee, Jae Seung Kim
We investigated the longitudinal changes in cortical tau accumulation and their association with cognitive decline in patients in the Alzheimer disease (AD) continuum using 2-(2-([18 F]fluoro)pyridin-4-yl)-9 H -pyrrolo[2,3-b:4,5c']dipyridine ([18 F]PI-2620) PET. Methods: We prospectively enrolled 52 participants (age, 69.7 ± 8.4 y; 18 men and 34 women): 7 with normal cognition, 28 with mild cognitive impairment, and 17 with AD. They all completed the [18 F]PI-2620 and [18 F]florbetaben PET, MRI, and neuropsychologic tests at baseline and, excepting the [18 F]florbetaben PET, at the 1-y follow-up...
February 1, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38302151/the-current-and-future-roles-of-precision-oncology-in-advanced-breast-cancer
#75
JOURNAL ARTICLE
Heather Jacene, Eric Dietsche, Jennifer Specht
Breast cancer is a common but heterogeneous disease characterized by several biologic features, including tumor grade, hormone receptor status, human epidermal growth factor receptor 2 status, and gene expression assays. These biologic and genomic features drive treatment decisions. In the advanced disease setting, inter- and intrapatient tumor heterogeneity is increasingly recognized as a challenge for optimizing treatment. Recent evidence and the recent approval of novel radiopharmaceuticals have increased recognition and acceptance of the potential of molecular imaging as a biomarker to impact and guide management decisions for advanced breast cancer...
February 1, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38302150/reply-18-f-fdg-and-lymphomas-still-a-winning-golden-couple-in-the-era-of-fapi-based-radiotracers
#76
LETTER
Xuetao Chen, Xuejuan Wang
No abstract text is available yet for this article.
February 1, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38302149/-18-f-fdg-and-lymphomas-still-a-winning-golden-couple-in-the-era-of-fapi-based-radiotracers
#77
LETTER
Priscilla Guglielmo, Laura Evangelista
No abstract text is available yet for this article.
February 1, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38272706/imaging-of-tumor-stroma-using-68-ga-fapi-pet-ct-to-improve-diagnostic-accuracy-of-primary-tumors-in-head-and-neck-cancer-of-unknown-primary-a-comparative-imaging-trial
#78
JOURNAL ARTICLE
Bingxin Gu, Ziyi Yang, Xinyue Du, Xiaoping Xu, Xiaomin Ou, Zuguang Xia, Qing Guan, Silong Hu, Zhongyi Yang, Shaoli Song
The low detection rate of primary tumors by current diagnostic techniques remains a major concern for patients with head and neck cancer of unknown primary (HNCUP). Therefore, in this study, we aimed to investigate the potential role of 68 Ga-labeled fibroblast activation protein inhibitor (68 Ga-FAPI) PET/CT compared with 18 F-FDG PET/CT for the detection of primary tumors of HNCUP. Methods: In this prospective comparative imaging trial conducted at Fudan University Shanghai Cancer Center, 91 patients with negative or equivocal findings of a primary tumor by comprehensive clinical examination and conventional imaging were enrolled from June 2020 to September 2022...
January 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38272705/it-s-a-trap-aldolase-prescribed-c-4-deoxyradiofluorination-affords-intracellular-trapping-and-the-tracing-of-fructose-metabolism-by-pet
#79
JOURNAL ARTICLE
Alexia Kirby, Dominic Graf, Mojmír Suchý, Nicholas D Calvert, Thomas A Charlton, Robert N Ben, Christina L Addison, Adam Shuhendler
Fructose metabolism has been implicated in various diseases, including metabolic disorders, neurodegenerative disorders, cardiac disorders, and cancer. However, the limited availability of a quantitative imaging radiotracer has hindered its exploration in pathology and diagnostic imaging. Methods: We adopted a molecular design strategy based on the catalytic mechanism of aldolase, a key enzyme in fructolysis. We successfully synthesized a radiodeoxyfluorinated fructose analog, [18 F]4-fluoro-4-deoxyfructose ([18 F]4-FDF), in high molar activity...
January 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38272704/first-in-human-evaluation-of-site-specifically-labeled-89-zr-pertuzumab-in-patients-with-her2-positive-breast-cancer
#80
JOURNAL ARTICLE
Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, Audrey Mauguen, Ryan Min, Sue Park, Julia P Brockway, Jacqueline F Bromberg, W Iris Zhi, Mark E Robson, Rachel Sanford, Shanu Modi, Brian J Agnew, Serge K Lyashchenko, Jason S Lewis, Gary A Ulaner, Brian M Zeglis
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these antibodies yields poorly defined and heterogeneous products with suboptimal in vivo performance. Here, we describe a first-in-human PET study on patients with HER2-positive breast cancer evaluating the safety, biodistribution, and dosimetry of 89 Zr-site-specific (ss)-pertuzumab PET, a site-specifically labeled radioimmunoconjugate designed to circumvent the limitations of random stochastic lysine labeling...
January 25, 2024: Journal of Nuclear Medicine
journal
journal
20164
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.